+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Search Bar & Filters

Found 49 Actively Recruiting clinical trials

O

Actively Recruiting

Researchers are evaluating the long-term safety, tolerability, and effectiveness of ML-007C-MA in adults with schizophrenia. This open-label Phase 2 study includes participants who have recently completed a previous related study or new participants enrolling directly. The study focuses on adults aged 18 to 65 diagnosed with schizophrenia who may benefit from ongoing pharmacotherapy and can maintain outpatient care. Participants will receive ML-007C-MA dosed at 2103 mg twice daily for up to 52 weeks. This single-group study does not involve placebo and assesses the medications impact over the treatment period. The study allows for continuous monitoring and adjustment based on the participants response and tolerability. During the study, participants will be involved in regular assessments to monitor safety and tolerability from the initial dose through the entire treatment period. Evaluations include clinical interviews, physical exams, ECGs, and laboratory tests to track any adverse effects or changes in health status. Researchers will also gather information from a reliable informant to support assessments. The total participation duration can be up to one year.

Age: 18Years - 65YearsAll GendersPhase 2
45 locations
P

Actively Recruiting

Researchers are evaluating the safety and effectiveness of KarXT combined with KarX-EC in adults aged 55 to 90 who experience agitation related to Alzheimers Disease. This Phase 3, randomized, double-blind, placebo-controlled study aims to better understand how these treatments may impact agitation symptoms in this population. The study is sponsored by Bristol-Myers Squibb and focuses on agitation as a complication of Alzheimers disease. Participants will be randomly assigned to receive either the combination of XanomelineTrospium Chloride Capsule and Xanomeline Enteric Capsule or a placebo. The treatments are given at specified doses on designated days. The study uses a parallel group design to compare these two options over a treatment period lasting up to 14 weeks. During the study, participants and their caregivers will attend regular visits for assessments including agitation severity using the Cohen-Mansfield Agitation Inventory-International Psychogeriatric Association total score, clinical global impressions, and other neuropsychiatric evaluations. Safety will be closely monitored through adverse event reporting and various clinical tests, including movement scales, vital signs, lab tests, ECGs, and assessments for suicidal thoughts. Caregivers will help oversee medication compliance and report on participant status. The entire study period extends through Week 18 for safety follow-up.

Age: 55Years - 90YearsAll GendersPhase 3
143 locations
P

Actively Recruiting

Researchers are evaluating AZD0780, an oral PCSK9 inhibitor, in a phase 3 randomized, double-blind, placebo-controlled study to assess its effect on reducing major adverse cardiovascular events in patients with established atherosclerotic cardiovascular disease ASCVD or those at high risk for a first ASCVD event. The study compares AZD0780 with a placebo and is event-driven, focusing on time to first cardiovascular events over approximately 54 months. Participants will be randomly assigned to receive either oral AZD0780 once daily or a matching placebo once daily. The study treatment continues from randomization until the primary analysis censoring date, followed by a study closure visit which marks the final visit for each participant. Background lipid-lowering therapy is maintained and expected to achieve significant LDL cholesterol reduction. The study design includes parallel treatment groups with quadruple masking to ensure unbiased results. During the study, participants attend regular visits for monitoring and assessments over a period that can last up to about 54 months. Researchers will measure the time to first major cardiovascular events including heart attack, stroke, urgent coronary revascularization, cardiovascular death, and other related outcomes. Safety and efficacy are carefully monitored through clinical evaluations, laboratory tests, and patient follow-up until study completion.

Age: 18Years +All GendersPhase 3
1452 locations
M

Actively Recruiting

Researchers are conducting an international, multicenter, randomized, controlled, open-label Phase III trial to evaluate the effectiveness and safety of libevitug in people with chronic Hepatitis Delta Virus HDV infection. The study focuses on participants aged 12 to 70 years who have a history of chronic HDV infection and specific liver enzyme levels. Participants will be assigned to one of three groups one group receiving libevitug at 20 mgkg every two weeks through intravenous infusion for 96 weeks another group receiving a lower dose of 10 mgkg on the same schedule and a control group observed for 48 weeks before then receiving the 20 mgkg libevitug dosage for the following 48 weeks. This setup allows comparison of different dosing and delayed treatment effects. Throughout the study, participants will undergo regular evaluations including liver function tests, viral load measurements, and liver stiffness assessments. The primary outcome is the proportion of participants achieving a significant reduction in HDV RNA and normalization of liver enzymes at week 48. Additional outcomes will be monitored up to week 120, including safety monitoring for adverse events. The total participation may last up to about two and a half years, with careful follow-up to assess long-term effects.

Age: 12Years - 70YearsAll GendersPhase 3
7 locations
S

Actively Recruiting

Researchers are evaluating the effect of a triple therapy inhaler containing budesonide, glycopyrronium, and formoterol fumarate BGF MDI 32014.49.6 g compared to a dual therapy inhaler with glycopyrronium and formoterol fumarate GFF MDI 14.49.6 g on heart and lung outcomes in adults with chronic obstructive pulmonary disease COPD who have increased cardiopulmonary risk. This is a Phase III randomized, double-blind, parallel group, multi-center study designed to assess these treatments over an extended period. Participants will be randomly assigned to receive either the triple therapy BGF MDI or the dual therapy GFF MDI, each administered twice daily. The study aims to track the time to first severe cardiac or COPD event over up to three years. Both treatments involve pressurized inhalation suspensions delivered by metered-dose inhalers, and the study includes ongoing monitoring for up to three years during which various cardiopulmonary events and exacerbations will be recorded. During the study, participants will attend visits where their inhaler technique, lung function, blood markers such as eosinophil counts, and COPD assessment test scores will be evaluated. Researchers will measure outcomes including time to severe COPD exacerbations, cardiac events, cardiopulmonary death, and hospitalizations related to heart issues. Safety and efficacy will be closely monitored throughout the study duration, which may last up to three years, with regular follow-up assessments conducted in person or virtually as needed.

Age: 40Years - 80YearsAll GendersPhase 3
922 locations
E

Actively Recruiting

Researchers are evaluating the effectiveness and safety of the drug ozanimod RPC1063 in treating pediatric participants aged 2 to 17 years who have moderate to severe active ulcerative colitis UC. These participants have not responded adequately to standard treatments. The study is a combined Phase 23, randomized, double-blind trial aimed at achieving and maintaining clinical remission in this population. Participants will receive oral ozanimod at different dose levels as part of the study. The treatment involves specified doses given on specific days. The study includes two experimental groups receiving either a high or low dose of ozanimod. The trial will assess outcomes over various time points, including up to 70 weeks for pharmacokinetics and safety monitoring, and follow-up for adverse events up to 6 years. During the study, participants will be closely monitored through clinical assessments, endoscopic evaluations, and laboratory tests. Researchers will measure remission rates, clinical responses, symptomatic remission, corticosteroid-free remission, endoscopic improvement, and lymphocyte counts. Safety will be tracked by documenting adverse events and serious adverse events throughout the study and follow-up period. The primary outcome is the proportion of participants achieving clinical remission at Week 52.

Age: 2Years - 17YearsAll GendersPhase 2Phase 3
91 locations
E

Actively Recruiting

Researchers are evaluating the safety and effectiveness of brenipatide combined with standard treatment compared to placebo with standard treatment in adults with schizophrenia. This phase 2 study aims to understand how brenipatide affects body weight and other clinical measures in this population. The trial is sponsored by Eli Lilly and Company and includes adults aged 18 to 55 years diagnosed with schizophrenia. Participants will be randomly assigned to receive either brenipatide or placebo, both administered by subcutaneous injection alongside their usual schizophrenia care. The study is double-blind, meaning neither participants nor researchers will know who receives the active drug or placebo. The trial consists of three periods a screening period of about one month, a treatment period lasting up to 12 months, and a follow-up period of approximately two months. During the study, participants will attend regular visits for assessments including body weight changes, cognitive testing, symptom severity scales, and functional capacity evaluations. Researchers will also monitor safety through laboratory tests and measure drug levels and immune responses. The total participation time may be up to 15 months, including screening, treatment, and follow-up to evaluate outcomes and safety comprehensively.

Age: 18Years - 55YearsAll GendersPhase 2
101 locations
E

Actively Recruiting

Researchers are evaluating the effectiveness and safety of praliciguat in adults diagnosed with biopsy-confirmed focal segmental glomerulosclerosis FSGS, a kidney disease. This Phase 2, randomized, double-blind, placebo-controlled, multicenter study compares praliciguat to a placebo over an initial 24-week period, followed by an open-label phase where all participants receive praliciguat for another 24 weeks. Those who respond to treatment may join a long-term safety extension study. Participants are randomly assigned to receive either praliciguat or a matching placebo daily during the 24-week double-blind period. After this, all participants take praliciguat daily during the 24-week open-label period. Dose escalation to a target dose occurs during the initial treatment phase. Responders are invited to continue in a long-term safety extension where praliciguat is administered daily. During the study, participants undergo regular assessments including urine protein-to-creatinine ratio UPCR measurements, monitoring for treatment-emergent adverse events, and plasma concentration tests of praliciguat. Safety is closely tracked through reports of adverse events during both treatment periods and the long-term extension. The total participation duration may extend up to more than 48 weeks depending on extension study enrollment.

Age: 18Years +All GendersPhase 2
30 locations
E

Actively Recruiting

Researchers are studying people with opioid use disorder OUD who have trouble falling or staying asleep. This trial evaluates the safety and tolerability of suvorexant, a medication being tested to see if it helps people with OUD sleep longer compared to a placebo, which looks like the medicine but contains no active drug. The study is a Phase 3, randomized, double-blind trial led by Merck Sharp & Dohme LLC. Participants are randomly assigned to receive either suvorexant or a matching placebo for up to about 8 weeks. Those in the suvorexant group start with 10 mg for the first three nights, which may be increased to 20 mg nightly at the investigators discretion. The placebo group receives an identical-looking pill with no active medication. The study compares sleep duration and monitors safety during this period. During the study, participants will be assessed for changes in total sleep time and wakefulness after sleep onset at baseline and at week 8. Researchers will track adverse events, serious side effects, and any treatment discontinuations due to side effects throughout up to 10 weeks. Substance abuse will be monitored at several time points. Participants will complete study visits and safety assessments to help understand how the medication affects sleep and overall health.

Age: 18Years - 70YearsAll GendersPhase 3
13 locations
R

Actively Recruiting

This research aims to evaluate the feasibility, safety, and tolerability of aticaprant as an additional treatment for adults with schizophrenia. The study focuses on stable participants receiving outpatient care and on a stable antipsychotic medication dose. It compares aticaprant with a placebo to understand how well participants can complete the study and assessments. Participants are randomly assigned to receive either aticaprant or a placebo during the double-blind treatment phase. The study includes monitoring for adverse events, vital signs, ECG, laboratory parameters, body weight, BMI changes, suicidality, and extrapyramidal symptoms. The treatment and observation period lasts up to 126 days with various assessment points. During the study, participants will undergo regular evaluations including safety checks, symptom assessments, and blood tests. Researchers will track completion rates of assessments and study milestones. Safety monitoring covers changes in vital signs, ECG, lab results, and mental health symptoms. The total participation time can be up to approximately four months.

Age: 18Years - 60YearsAll GendersPhase 1
8 locations

1-10 of 49

1